Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2026 07:00 ET | Source: Arch Biopartners

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient...
April 23, 2026 06:15 ET | Source: Equity Insider

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB: AVAI), Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Viking Therapeutics,...
April 20, 2026 05:19 ET | Source: Novo Nordisk A/S

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease

Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1Haemoglobin response was superior with...
March 19, 2026 11:40 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.
March 17, 2026 09:00 ET | Source: Portnoy Law

Novo Nordisk A/S Investigated by the Portnoy Law Firm

LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S (“Novo Nordisk" or the "Company") (NYSE:NVO) investors that the firm has initiated an investigation into...
March 17, 2026 05:28 ET | Source: Digbi Health

Digbi Health Capitalizes on GLP-1 Market Shift, Expands GLP Compass™, and Introduces Employer-Subsidized and Cash-Pay Pathways via Digbi RxFund™

This industry-first financial innovation bypasses PBM spread pricing, ensures ERISA compliance, gives employers total control over the Budget, Behavior, an
February 25, 2026 09:56 ET | Source: Schall Law

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
February 09, 2026 07:28 ET | Source: Arch Biopartners

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the...
February 05, 2026 19:53 ET | Source: PharmaZee

PharmaZee GLP-1 Prescription Information Updated as Novo Nordisk Raises Compounding Concerns and Consumer Interest in Telehealth Semaglutide Access Grows in 2026

PharmaZee telehealth platform information updated. Examining compounded vs FDA-approved GLP-1s amid Novo Nordisk compounding statement Feb 2026.
January 16, 2026 08:15 ET | Source: Arch Biopartners

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the...